India Remdesivir Market To Establish Growth Due To Rapid Technological Advancement Until FY2027
Increasing prevalence of the
targeted diseases is driving the growth if India Remdesivir Market,
FY2017-FY2027.
According to
TechSci report on, “India Remdesivir Market By Technology (16-Slice,
32-Slice, 8-Slice, 64-Slice, 128 & Above Slice) By Modality (Fixed v/s
Mobile) By Device Architecture (C-arm v/s O-arm) By Application (Cardiology,
Oncology, Neurology, Others) By End Users (Diagnostic Centers, Hospitals,
Others) By Region, Competition Forecast & Opportunities, FY2027”, India Remdesivir market
has shown promising growth in historical years until FY2020 and is expected to
continue its growth in upcoming forecast years FY2023 to FY2027. India Remdesivir
market owes its growth to the factors like increasing number of the COVID-19 patients
in the country along with the surge in the demand with the increasing
prevalence of viral diseases like hepatitis, Ebola, COVID-19. Manufacturers are
actively involved with the large production of the drug due to the surge in the
demand. While the limited knowledge about the safety and efficiency regarding
using Remdesivir to treat patients with COVID-19 at hospital and high cost of
Remdesivir is expected to obstruct the growth of the Remdesivir market in the
above mentioned forecast period. Additionally, the high R&D investment is
also lifting the growth of the Remdesivir market.
Remdesivir is an antiviral medication
that is developed by the biopharmaceutical company Gilead Sciences.
Administered via injection into a vein, the drug manufacturing process started
in March 2020 with a research performed by Gilead Sciences Inc. The research
was performed on 53 prospective COVID-19 patients out of which only 36 patients
showed signs of progress that accounted for about 68% of the total number of
patients. World Health Organization has guided the start of clinical trials for
the drug along with three other drugs found to be effective in COVID-19
therapy. Remdesivir drug has reached phase 3 of clinical trials and the world
hopes it will emerge as a promising treatment for COVID-19. Following these
positive trials, the food and drug administration issued permission for the
medication to treat Covid-19 for emergency use authorization (EUA). That means
the medication has not undergone the same examination as therapies approved by
the FDA, but it will allow doctors to prescribe Remdesivir to patients
hospitalized with the disease. All supply of drugs will go to the government
for allocation across the nation.
Browse over XX market data Figures spread through 70 Pages and an
in-depth TOC on "India Remdesivir Market"
https://www.techsciresearch.com/report/india-remdesivir-market/7551.html
India Remdesivir market segmentations is
based on application, route of administration, dosage form, patient age,
distribution channel, competitional landscape, and regional distribution. Based
on route of administration, the market is further divided between inhalation, intravenous.
Intravenous administration is anticipated to hold the larger share of the
revenue market and assert the dominance over the market on the account of availability
of the drugs in the process. Based on dosage form, the market is further
bifurcated into frozen solution, lyophilized solution. The Remdesivir drug is
transported by the suppliers in two forms, frozen solution and lyophilized
solution. Frozen form of the drug is anticipated to be able to store the drug
for longer duration. Cold chain storages and logistics are utilized to
distribute the drug from the manufacturer joints to the end users like
hospitals, pharmacies etc. Lyophilized solution is the powdered solution of the
Remdesivir drug that is solubilized with sterile water and saline.
Some of the top players in the India
Remdesivir Market are, Cipla Ltd., Hetero Labs Pvt. Ltd., Jubilant Life
Sciences Ltd., Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt.
Ltd.), Dr. Reddy’s Laboratories Ltd., Sun Pharmaceuticals Industries Ltd.,
Zydus Cadila Healthcare Ltd., Pfizer Ltd., Gilead Sciences India Private
Limited, Eva Pharma Pvt. Ltd., among others. The companies are involving
themselves into research and development for more advanced form of the drug.
Remdesivir is the therapeutic drug against the coronavirus, COVID-19 and are in
demand owing to the need of the healthcare industry in the country. Although
the export of the drug is increasing rapidly to satisfy the consumer demand.
New players entering the market may form partnerships with other players or the
end users of the industry for a consistent inflow of the product.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7551
Customers can also request for
10% free customization on this report.
“With the
increasing demand of the cure for coronavirus, Remdesivir along with other
drugs have instigated the market, due to increased demand and lack of viable
drugs. Although the country is still exporting the drug from other countries,
the manufacturers available in the country are currently issuing this as an
emergency use drug only to treat the patients suffering from extreme conditions
of COVID-19,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“India Remdesivir Market By Technology (16-Slice,
32-Slice, 8-Slice, 64-Slice, 128 & Above Slice) By Modality (Fixed v/s
Mobile) By Device Architecture (C-arm v/s O-arm) By Application (Cardiology,
Oncology, Neurology, Others) By End Users (Diagnostic Centers, Hospitals, Others)
By Region, Competition Forecast & Opportunities, FY2027” has evaluated the future
growth potential of India Remdesivir market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in India Remdesivir market.
Contact
Mr. Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Web: https://www.techsciresearch.com/